HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Aptose Biosciences (NASDAQ:APTO) and raises the price target from $12 to $23.
June 12, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aptose Biosciences' price target has been raised from $12 to $23 by HC Wainwright & Co. analyst Joseph Pantginis, who maintains a Buy rating on the stock.
The news of HC Wainwright & Co. analyst Joseph Pantginis maintaining a Buy rating on Aptose Biosciences and raising the price target from $12 to $23 is positive for the stock. This increased price target indicates a higher potential upside for the stock, which is likely to attract more investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100